News

The TRIC-I-HF trial demonstrated that transcatheter tricuspid valve repair plus optimal medical therapy was superior to medical therapy alone in patients with symptomatic severe tricuspid regurgitation and heart failure. The intervention reduced all-cause death and HF hospitalization with benefits emerging early and sustained to 3 years, along with meaningful quality of life improvements.

Digest: This represents the first time transcatheter tricuspid repair has shown significant reductions in hard clinical endpoints (mortality and HF hospitalization), not just quality of life, potentially establishing a new standard of care for severe tricuspid regurgitation patients.

The phase 3 LIBREXIA trial evaluating milvexian, an oral factor XIa inhibitor, was halted early for futility in patients with recent acute coronary syndrome at high risk for recurrent ischemic events. Milvexian added to antiplatelet therapy did not reduce cardiovascular death, MI, or ischemic stroke compared with placebo, though no excess bleeding risk was observed.

Digest: This trial demonstrates that factor XIa inhibition does not provide additional ischemic protection in ACS patients on antiplatelet therapy, though the lack of bleeding signal may inform ongoing anticoagulation strategies in structural heart interventions where thrombotic and hemorrhagic balance is critical.

The article discusses how expert clinical practice guidelines have shaped decision-making between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). Specific data or findings are not provided in the submitted article content.

Digest: Guideline recommendations directly influence treatment algorithms and patient selection criteria, affecting procedural volumes, reimbursement patterns, and competitive positioning in the structural heart market.